A New York-based healthcare investment firm has announced that it has raised $1.86 billion in commitments for OrbiMed Royalty ...

Germany’s BioNTech has reported revenues for the second quarter 2025 of 260.8 million euros ($302 million), more than double ...

Swedish biotech Hansa Biopharma on Friday released encouraging top-line results from three patients with Duchenne muscular ...

The US Food and Drug Administration (FDA) has approved a label update for Swiss pharma giant Novartis’ Leqvio (inclisiran), ...

Biosimilars, once met with skepticism, are now an undeniable force in the global pharmaceutical market. As several ...

Philadelphia, USA-based Medicus Pharma and Boston-based biotech Helix Nanotechnologies have entered into a non-binding ...

Chinese biotech Mabgeek Biotechnology has filed to go public in Hong Kong, seeking to raise funds to support development of ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla (donanemab-azbt) continued to demonstrate ...

Allogene Therapeutics, a US biotech developing allogeneic CAR T products for cancer and autoimmune disease, closed 12% lower ...

New York-based Spine BioPharma on Friday revealed disappointing results with its growth factor beta (TGF-β) antagonist, SB-01 ...

Founded by experts in psychiatry and neuroscience to target neural circuits causally linked to disease, the company employs ...

A clinical‑stage biotech company developing gene therapies to treat common joint diseases such as knee osteoarthritis, which ...